NEW YORK, NY – November 10, 2015 -- InvestorsHub NewsWire -- Small Cap Street makes the connection between sophisticated investors and high quality micro and small cap companies that are currently undervalued. We are an issuer of reports written by experienced financial analysts and who provide a straight forward assessment of a profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

*Feature Analyst Alert*

This week's NASDAQ alert is the lowest priced with the most upside potential that we have covered in a long time. Another reason we like this one so much their technology is proprietary. (NASDAQ: AMDA) is in the hot biotech / biomaterial space currently holding 56 patents issued and another 37 patents pending. As if that's not enough to get you excited, (NASDAQ: AMDA) has earnings due this week Thursday November 12th, 2015.

Earnings PR- http://finance.yahoo.com/news/amedica-corporation-release-third-quarter-201500678.html

Link to Amedica's Investor presentation at their website- http://investors.amedica.com/downloads.cfm

Link to Amedica's website providing information on the two analyst' that cover their securities Needham and JMP Securities - http://investors.amedica.com/analysts.cfm

Needham and JMP's targets are $1 and $3/share.

If you would like to receive profiles in real time, text "Street" to 25827

4 Brief Investor Updates

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) is a pharmaceutical company developing a pipeline of abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers to entry. Elite owns generic and OTC products licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International with eight commercial products currently being sold.

The company just announced that revenue for its fiscal quarter ended September 30, 2015 had more than doubled over the same period a year ago. In October the company announced positive results from the Phase 3 trial of its lead abuse-deterrent opioid, ELI-200, for the treatment of moderate to severe pain. The Company plans to file a New Drug Application with the FDA later this year.

Plug Power, Inc. (NASDAQ: PLUG) is in the hydrogen fuel cell technology business.  Its signature solution, GenKey, provides an all-inclusive package for customers, incorporating GenFuel hydrogen and fueling infrastructure, GenCare aftermarket service and either GenDrive or ReliOn fuel cell systems.

PLUG has released its financial data for the quarter ended September 30, 2015. According to the company statement they are meeting the guidance metrics they established at the beginning of this year. The company experienced a loss in the quarter of $10.2 million or $.06 per share.

Innovativ Media Group, Inc. (OTCBB: INMG) is a developer, producer and distributor of digital entertainment and other multi-media content. It manages a library of feature films and operates New Broadway Cinema, The Alien Channel, VOD Movie Guide and the Film Finance Exchange.

INMG had a big trading day yesterday, November 9, 2015. Shares closed at $.0005 up 66% and trading volume was 244 million shares almost ten times the daily average.

EP Global Communications, Inc. (OTCBB: EPGL) is an advanced technology research and development company for both medical devices and consumer electronics devices specializing in microelectronic mechanical systems (MEMS).
EPGL has patented technologies for augmented vision and electronic vision correction. In 2013, EPGL signed its first Development Agreement with Coopervision, Inc. for its "Energy Harvesting" contact lens technology. The two companies are negotiating the formula for EPGL to get compensated for the technology's development.

Forward-Looking Disclaimer   
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Compliance Procedure   
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only.  A full disclaimer can be found by viewing the full analyst report. We do not engage in high frequency trading or hold any positions of profiled company.

For more information and services provided beyond this release please use contact information provided below. If you notice any errors or omissions, please notify us below.

Source: Small Cap Street

Contact: editor@smallcapstreet.com
 

Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Elite Pharmaceuticals (QB) Charts.
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Elite Pharmaceuticals (QB) Charts.